Table 4.
Account (%) |
|||
---|---|---|---|
Adverse event | VDG n = 150 | PG n = 152 | pb |
Any treatment-related adverse event | 46 (30.7) | 48 (31.6) | 0.864 |
Headache | 8 (5.3) | 18 (11.8) | 0.044 |
Constipation | 15 (10.0) | 7 (4.6) | 0.071 |
Diarrhea | 7 (4.7) | 8 (5.3) | 0.811 |
Nausea | 7 (4.7) | 3 (2.0) | 0.191 |
Abdominal pain | 5 (3.3) | 2 (1.3) | 0.244 |
Dizziness | 3 (2.0) | 6 (3.9) | 0.320 |
Drowsiness | 9 (6.0) | 9 (5.9) | 0.977 |
Muscular weakness | 6 (4.0) | 8 (5.2) | 0.602 |
Vomiting | 1 (0.7) | 0 (0) | 0.313 |
Values are n (%);
Statistics was conducted with χ2 analysis.